244 related articles for article (PubMed ID: 29842934)
21. Core-shell cisplatin/SiO
Li W; Solenne TOSB; Wang H; Li B; Liu Y; Wang F; Yang T
Acta Biomater; 2023 Oct; 170():273-287. PubMed ID: 37597681
[TBL] [Abstract][Full Text] [Related]
22. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance.
Lee JH; Suh JH; Kang HJ; Choi SY; Jung SW; Lee-Kwon W; Park SA; Kim H; Ye BJ; Yoo EJ; Jeong GW; Park NH; Kwon HM
EBioMedicine; 2020 Aug; 58():102926. PubMed ID: 32739873
[TBL] [Abstract][Full Text] [Related]
23. TR4 nuclear receptor enhances the cisplatin chemo-sensitivity via altering the ATF3 expression to better suppress HCC cell growth.
Shen J; Lin H; Li G; Jin RA; Shi L; Chen M; Chang C; Cai X
Oncotarget; 2016 May; 7(22):32088-99. PubMed ID: 27050071
[TBL] [Abstract][Full Text] [Related]
24. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
[TBL] [Abstract][Full Text] [Related]
25. Knockdown of mutated H-Ras V12 expression induces chemosensitivity of hepatocellular carcinoma cells to cisplatin treatment in vitro and in nude mouse xenografts.
Meng F; Cao B; Feng Z; Ma S; Wang H; Li Y; Li H
Oncol Rep; 2014 Nov; 32(5):2023-30. PubMed ID: 25189269
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma.
Wang Y; Huang F; Cai H; Wu Y; He G; Tan WS
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1827-37. PubMed ID: 20213096
[TBL] [Abstract][Full Text] [Related]
27. lncARSR promotes liver cancer stem cells expansion via STAT3 pathway.
Yang C; Cai WC; Dong ZT; Guo JW; Zhao YJ; Sui CJ; Yang JM
Gene; 2019 Mar; 687():73-81. PubMed ID: 30391438
[TBL] [Abstract][Full Text] [Related]
28. Nigericin selectively targets cancer stem cells in nasopharyngeal carcinoma.
Deng CC; Liang Y; Wu MS; Feng FT; Hu WR; Chen LZ; Feng QS; Bei JX; Zeng YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):1997-2006. PubMed ID: 23831840
[TBL] [Abstract][Full Text] [Related]
29. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
30. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
32. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375.
Yang T; Zhao P; Rong Z; Li B; Xue H; You J; He C; Li W; He X; Lee RJ; Ma X; Xiang G
Theranostics; 2016; 6(1):142-54. PubMed ID: 26722380
[TBL] [Abstract][Full Text] [Related]
34. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse Xenograft models of human hepatocellular carcinoma.
Hou H; Sun H; Lu P; Ge C; Zhang L; Li H; Zhao F; Tian H; Zhang L; Chen T; Yao M; Li J
Mol Cancer Ther; 2013 Dec; 12(12):2874-84. PubMed ID: 24130050
[TBL] [Abstract][Full Text] [Related]
35. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
[TBL] [Abstract][Full Text] [Related]
36. Preclinical evaluation of cisplatin-incorporated bio-nanocapsules as chemo-radiotherapy for human hepatocellular carcinoma.
Shin SH; Park SS; Lee KJ; Ju EJ; Park J; Ko EJ; Jung J; Kuroda S; Hong SM; Hwang JJ; Lee JS; Song SY; Jeong SY; Choi EK
Oncol Rep; 2017 Oct; 38(4):2259-2266. PubMed ID: 28849069
[TBL] [Abstract][Full Text] [Related]
37. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
38. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells.
Lan X; Wu YZ; Wang Y; Wu FR; Zang CB; Tang C; Cao S; Li SL
Int J Mol Med; 2013 Feb; 31(2):315-24. PubMed ID: 23233126
[TBL] [Abstract][Full Text] [Related]
39. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
